睿知中国疾病研究地图
候选清单0

正在招募骨肉瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

ClinicalTrials.gov 上登记的一项骨肉瘤开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月13日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07648069,读取于 2026年11月13日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;

    入选标准第 3 条

  3. 1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.

    排除标准第 1 条

    Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:

    排除标准第 2 条

  4. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;

    入选标准第 9 条

    platelet ( PLT ) ≥ 75 × 109 / L;

    入选标准第 11 条

    hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;

    入选标准第 12 条

    serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;

    入选标准第 15 条

    Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;

    入选标准第 16 条

    Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;

    入选标准第 17 条

    total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.

    入选标准第 18 条

    absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;

    排除标准第 4 条

    platelet ( PLT ) ≥ 75 × 109 / L;

    排除标准第 6 条

    hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;

    排除标准第 7 条

    serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;

    排除标准第 10 条

    Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;

    排除标准第 11 条

    Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;

    排除标准第 12 条

    total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.

    排除标准第 13 条

  5. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;

    入选标准第 6 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;日常活动能力;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07648069,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
  2. Age≥18 years old, and≤70 years old ;
  3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ;
  4. Patients with first-line treatment failure ;
  5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ;
  6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ;
  7. The following three screening indicators should be met in the test screening period:
  8. White blood cell count ≥ 3.0 × 109 / L;
  9. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
  10. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
  11. platelet ( PLT ) ≥ 75 × 109 / L;
  12. hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
  13. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
  14. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
  15. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
  16. Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
  17. Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
  18. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.

排除标准:Exclusion Criteria:

  1. 1. Before any procedures related to the research program, including screening and evaluation stage, signed informed consent.
  2. Age≥18 years old, and≤70 years old ; 3. Pathologically diagnosed as solid tumors, including bone or soft tissue sarcoma, and staging for advanced or unresectable patients ; 4. Patients with first-line treatment failure ; 5. No previous tumor vaccine treatment ; no previous treatment with PD-1 antibody ; 6. According to the RECIST1.1 standard, there are measurable lesions and superficial lesions ; 7. The following three screening indicators should be met in the test screening period:
  3. White blood cell count ≥ 3.0 × 109 / L;
  4. absolute neutrophil count ( ANC ) ≥ 1.5 × 109 / L ( without GCSF support ) ;
  5. absolute lymphocyte count ( ALC ) ≥ 1.0 × 109 / L;
  6. platelet ( PLT ) ≥ 75 × 109 / L;
  7. hemoglobin ≥ 90g / dL ( no blood transfusion in the past 7 days ) ;
  8. Prothrombin time or INR ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
  9. partial thromboplastin time ( APTT ) ≤ 1.5x normal upper limit time, unless receiving anticoagulant therapy;
  10. serum creatinine ≤ 1.5 × ULN ( upper limit of normal ) ; 24-hour creatinine clearance rate ≥ 60 mL / min;
  11. Aspartate Aminotransferase (AST/SGOT) ≤ 2 × ULN;
  12. Alanine Aminotransferase (ALT/SGPT) ≤ 2 × ULN;
  13. total bilirubin ( TBIL ) ≤ 1 × ULN 13. Females with fertility were negative in pregnancy test before treatment ; consent must be given to the use of contraception or the prohibition of same-sex or opposite-sex sexual activity during treatment; 14. During the whole experiment, we can regularly go to the research institutions to carry out relevant testing, evaluation and management.

引自 ClinicalTrials.gov, NCT07648069, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07648069,读取于 2026年11月13日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07648069